The FDA assessed the protection and effectiveness of atidarsagene autotemcel according to data from 37 small children who acquired atidarsagene autotemcel in two single-arm, open-label medical trials As well as in an expanded obtain software.[7] Small children who acquired remedy with atidarsagene autotemcel were as compared to untreated young chil